223 related articles for article (PubMed ID: 20597681)
1. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
2. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
4. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Ijaz K; McElroy PD; Navin TR
Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
[No Abstract] [Full Text] [Related]
6. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
7. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
8. Tuberculosis control programme guidelines--treatment regimens.
Durrheim DN; Belt EL
S Afr Med J; 1996 Oct; 86(10):1293-4. PubMed ID: 8955740
[No Abstract] [Full Text] [Related]
9. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
Garca-Doval I
J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
[No Abstract] [Full Text] [Related]
10. Drugs for tuberculosis.
Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
[No Abstract] [Full Text] [Related]
11. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of tuberculosis in the adult].
Schrappe M; Wassermann K; Kroegel C
Med Klin (Munich); 1995 Apr; 90(4):229-30. PubMed ID: 7776936
[No Abstract] [Full Text] [Related]
13. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
14. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
15. Antituberculous therapy and acute liver function.
Bourke SJ; White J; Stenton SC; Hendrick DJ
Lancet; 1995 May; 345(8958):1171-2. PubMed ID: 7786347
[No Abstract] [Full Text] [Related]
16. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
17. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
18. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Srivastava S; Deshpande D; Magombedze G; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
[TBL] [Abstract][Full Text] [Related]
19. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
20. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Lambert LA; Ijaz K; Navin TR
Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
